Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

HRGN Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: January 15, 2025

Report Source: 2024 3rd Quarter Report

Harvard Apparatus Regenerative Technology Inc

Harvard Apparatus Regenerative Technology Inc. Stock Analysis HRGN

United States Health Care Nano Cap Report:
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. The company is headquartered in Holliston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2013-10-14. The firm's technology is based on its cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. The firm is advancing its Cellspan esophageal implant product candidate through an Investigator-Initiated Trial targeting pediatric patients with Esophageal Atresia. Its biocompatible scaffold component of its esophageal implant is constructed primarily of thin polyurethane fibers. Its other product candidates in development pipeline are targeted at the reconstruction of the colon and uterus wound repair. The Company, through its subsidiary, Harvard Apparatus Regenerative Technology Limited, is focused on personal healthcare, including dietary supplements.
Read More

Harvard Apparatus Regenerative Technology Inc (HRGN) Chart

Key Statistics of Harvard Apparatus Regenerative Technology Inc (HRGN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$1.10$1.24

Today's Open

$1.10

Volume

200.00

P/E Ratio (TTM)

-

52 Week Range

$0.96$2.22

Market Cap

24.61M

Avg. Volume

876.47

Dividend Yield

-

Financial Metrics & Statements of Harvard Apparatus Regenerative Technology Inc (HRGN)

FAQ's for Harvard Apparatus Regenerative Technology Inc (HRGN)

  • According to Musaffa’s Shariah screening methodology, Harvard Apparatus Regenerative Technology Inc (HRGN) is currently classified as HALAL as of January 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Harvard Apparatus Regenerative Technology Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Harvard Apparatus Regenerative Technology Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Harvard Apparatus Regenerative Technology Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Harvard Apparatus Regenerative Technology Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Harvard Apparatus Regenerative Technology Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.